P&G to work with FDA over 'illegal' Vicks cold product

By Shane Starling

- Last updated on GMT

Related tags Dietary supplement

Procter & Gamble says it is working with the Food and Drug Administration (FDA) to address the issues that caused the regulator to issue a warning letter over vitamin C-fortified cold and flu remedies.

Ohio-based P&G spokesperson Crystal Harrell said P&G believed it was, “marketing within FDA guidelines and regulations” ​about the products in question - ​Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C.

She said her company wanted to better understand the regulations in relation to products that contained both pharmaceutical and dietary supplement ingredients, and was working with the FDA towards this end.

The company has 15 days to alert the FDA of its intended actions and Harrell said no product withdrawal had been demanded or actioned by the company, despite the fact the FDA stated the products, are illegally marketed combinations of drug ingredients and a dietary ingredient.”

The FDA said it acted to, “clarify that these single dosage form combinations of drug ingredients and dietary ingredients legally cannot be marketed because they have not been proven safe and effective.”

It also noted that: “The agency previously determined that there are insufficient data to show that vitamin C is safe and effective in preventing or treating the common cold.”

Under its OTC monograph system, the FDA allows some OTC drugs to be marketed without agency approval. Such drugs must comply with applicable monographs, which are regulations that set requirements for the drugs' labeling, formulations and indications. The two Vicks products do not comply with the applicable FDA monograph and must first be evaluated and approved under the FDA’s new drug approval process to be legally marketed.”

The FDA cited former cases involving​Bayer HealthCare in 2008 and Omni Nutraceuticals in 2001 that saw combination products incur the wrath of the regulator.

Harrell noted the latest warning letter had not arrived in addition to a previously issued warning letter about the same products that the FDA subsequently withdrew over an administrative mix-up.

The products have been available in the US since July, 2008.

The ruling can be found her​e.

Related news

Related products

show more

An Innovative Prebiotic to Support Microbiome Balance

An Innovative Prebiotic to Support Microbiome Balance

Content provided by Deerland Probiotics & Enzymes | 06-Nov-2023 | Product Brochure

PreforPro® is a clinically supported prebiotic that supports the growth of healthy bacteria in the gut by utilizing phage technology.

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Innovation In Joint and Women's Health

Innovation In Joint and Women's Health

Content provided by Arjuna Natural LLC-USA | 02-Oct-2023 | Product Presentation

The joint health space is a crowded market and can be difficult to create new and exciting innovation. The team at Arjuna Natural created Rhuleave-K®,...

Tap into SGS Nutrasource’s Expertise

Tap into SGS Nutrasource’s Expertise

Content provided by Nutrasource Pharmaceutical and Nutraceutical Services | 29-Sep-2023 | Infographic

At SGS Nutrasource, our commitment to quality and compliance excellence has grown stronger. Leveraging our two decades of experience in regulatory, clinical,...

Related suppliers

Follow us


View more